Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2001

View Archived Issues

Amsterdam biotechnology company licenses DKFZ's AAV vector technology

Human antibody alliance expanded by Abgenix and Chiron

InterMune updates development status of Actimmune

Dose-dependent response reported by La Jolla for LJP-394 at recent lupus conference

Aradigm receives milestone payment for development of AERx Diabetes Management System

Epimmune and Elan establish licensing agreement for PADRE technology

Development of therapeutics targeting CXCR4 accelerated at Northwest Biotherapeutics

Health Canada approves Allergan's Botox for treatment of glabellar lines

Synaptic on track to file IND for lead antidepressant drug candidate

Met-enkephalin shows potential as an AIDS therapeutic vaccine

Secretin reported to produce significant clinical response in autism

First phase III results for IC-351 discussed by Lilly Icos at EAU meeting

AstraZeneca beta-blocker now available in U.S. for heart failure treatment

Alzheimer's disease development candidate related to donepezil identified at Eisai

Potent, orally active anorectic agents identified in DuPont 5-HT2C ligand program

RWJ-58259 characterized simultaneously at ACS and in major scientific journal

Zometa approved in E.U. for TIH treatment

University of Pittsburgh researchers begin study of rofecoxib for prevention of colon polyps

U.S. university investigators identify antitrypanosomal dicationic reversed amidines

Nymox study confirms link between spherons and senile plaques

Targeted anticancer agent featured in New England Journal of Medicine

Use of modafinil in anorexia

Combination therapies for restless legs syndrome devised by Boehringer Ingelheim

Schering-Plough patents use of antiallergic agents for CNS, vascular disorders

GABA-A receptor ligands from MS&D particularly useful in anxiety Rx

Antibacterial 9a-azalide series described in recent patent by Abbott

NPY antagonists with selectivity for Y5 receptors and their use in eating disorders

Series of potent and selective tryptase inhibitors discovered at Morphochem

ConjuChem progresses clinical studies of two products during fiscal Q1 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...